GB Sciences Cannabis Supplier to U.S. Marijuana Researchers

by | Sep 3, 2019

GB Sciences Submitted One of Thirty-Three Applications to Become a DEA-Registered Cannabis Supplier to U.S. Marijuana Researchers

GB Sciences GBLX

GB Sciences, Inc. (OTCQB: GBLX) today announced that it has received notification from the U.S. Drug Enforcement Agency (DEA) that prior to making any decisions on the pending applications, the DEA intends to distribute regulations that govern the program of growing marijuana for scientific research under DEA registration. GB Sciences is one of just 33 companies that applied to the DEA to become registered under the Controlled Substances Act (CSA) to grow (manufacture) marijuana in order to supply DEA-registered researchers in the United States. Last week, after a three-year delay and following pressure by Congress, patients and researchers, the DEA announced that it will move forward with creating revised regulations and with reviewing the applications.

 

GB Sciences’ 28,000-square-foot facility in Las Vegas, Nevada features one of the only pharmaceutical-grade “cleanroom-type” grows in the United States. The company’s groundbreaking research program, led by Dr. Small-Howard with nine university research partners in the U.S. and internationally, has created a patent portfolio of cannabis-based therapies that cover over 60 disease and health conditions including Parkinson’s disease, neuropathic pain, and cardiac hypertrophy.

To read the entire article click below:
https://www.prnewswire.com/news-releases/us-drug-enforcement-agency-to-expand-cannabis-research-gb-sciences-submitted-one-of-thirty-three-applications-to-become-a-dea-registered-cannabis-supplier-to-us-marijuana-researchers-300910389.html

Related Links
http://gbsciences.com/

About GB Sciences

About GB Sciences
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company’s goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.

 

Share This